Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Theratechnologies Inc. - Common Shares (NQ:THTX)

3.232 -0.009 (-0.26%)
Streaming Delayed Price Updated: 2:49 PM EDT, Aug 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Theratechnologies Inc. - Common Shares

< Previous 1 2 3 4 Next >
Theratechnologies Receives 2023 CQDM ADRIQ RSRI Innovation Award
Honor awarded last night recognizes Theratechnologies and Prof. Borhane Annabi for advancing preclinical development of sudocetaxel zendusortide for treatment of triple-negative breast cancer 
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Closing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Pricing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Proposed Public Offering of Common Shares and Concurrent Private Placement
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Operational Update
From Theratechnologies
Via GlobeNewswire
Theratechnologies’ Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIV
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Finalization of Amendments to Some of the Terms and Conditions of its Credit Agreement with Marathon
From Theratechnologies
Via GlobeNewswire
Theratechnologies Presents Data at ID Week Showing Tesamorelin Reduces Visceral Adipose Tissue (VAT) and Liver Fat in People with HIV on Integrase Inhibitors (INSTIs)
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Results from Trogarzo® (Ibalizumab-uiyk) Intramuscular Administration Study
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Dosing of First Patient in Updated Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
From Theratechnologies
Via GlobeNewswire
Theratechnologies Receives January 2024 PDUFA Goal Date for Tesamorelin F8 Formulation sBLA
From Theratechnologies
Via GlobeNewswire
Theratechnologies Reports Financial Results for the Third Quarter and Nine Months of Fiscal 2023 and Provides Business Updates
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Agreement in Principle with Marathon to Amend Some of the Terms and Conditions of its Loan Facility
From Theratechnologies
Via GlobeNewswire
Theratechnologies Submits Tesamorelin F8 Formulation sBLA for FDA Review
From Theratechnologies
Via GlobeNewswire
Theratechnologies to Present at the Cantor Fitzgerald Global Healthcare Conference 2023
From Theratechnologies
Via GlobeNewswire
Theratechnologies to Announce Third Quarter 2023 Financial Results and Provide Business Update
From Theratechnologies
Via GlobeNewswire
Theratechnologies to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces All U.S. Oncology Clinical Sites Now Enrolling for Phase 1 Trial of Sudocetaxel Zendusortide
From Theratechnologies
Via GlobeNewswire
Theratechnologies Completes 1-for-4 Reverse Stock Split
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Amendments to its Term Loan Facility With Affiliates of Marathon Asset Management
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces the Resignation of One of Its Directors, Mr. Gary Littlejohn
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces 1-for-4 Reverse Stock Split
From Theratechnologies
Via GlobeNewswire
Theratechnologies Reports Second Quarter 2023 Financial Results and Business Updates
From Theratechnologies
Via GlobeNewswire
Theratechnologies to Announce Second Quarter 2023 Financial Results and Provide Business Update
From Theratechnologies
Via GlobeNewswire
Theratechnologies Draws Down on US$20 Million Second Tranche Under its Term Loan Facility With Affiliates of Marathon Asset Management
From Theratechnologies
Via GlobeNewswire
Theratechnologies June 13 Oncology Investigator Call to Update Investors & Analysts on Phase 1 Sudocetaxel Zendusortide Trial
From Theratechnologies
Via GlobeNewswire
Theratechnologies Receives FDA Agreement to Amended Trial Protocol for its Lead PDC Candidate Sudocetaxel Zendusortide
From Theratechnologies
Via GlobeNewswire
Theratechnologies to Present Preliminary Safety and Efficacy Data from Phase 1 Trial of Sudocetaxel Zendusortide in Heavily Pretreated Cancer Patients at ASCO 2023
From Theratechnologies
Via GlobeNewswire
Theratechnologies Reports on its Annual Meeting of Shareholders
From Theratechnologies
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.